Építés alatt – nem éles oldal
Belépés
Leállítva1/2. fázis

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

A legfontosabb adatok

Ki végzi
Ascendis Pharma Oncology Division A/S
Hol
Canton, Chicago, Cincinnati, Cleveland, Dallas, Duarte, Fairfax, Houston, Iowa City, Knoxville, Los Angeles, Louisville, Orange, Pittsburgh, San Francisco és Tampa (Egyesült Államok)Mind a 16 helyszín megnézéseMég 5 másik országban, 21 helyszínen
Azonosító
Állapot
Leállítva
Fázis
1/2. fázis
Résztvevők
188 fő vett részt
Kezdés
2021. márc. 18.
Befejezés
2025. dec. 2.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • TransCon TLR7/8 Agonist
  • Pembrolizumab
A regiszteradat frissítve
2026. április 13.
Miért állt le
The Sponsor made the decision to close enrollment to prioritize our efforts on TransCon IL-2 ß/g.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • At least 18 years of age
  • Participants must have histologically confirmed locally advanced, recurrent or metastatic solid tumor malignancies that cannot be treated with curative intent (surgery or radiotherapy)
  • Participants must have progressed on or be intolerant of available standard of care treatment options or have disease for which there is no standard of care treatment available, with the exception of participants enrolling to the neoadjuvant cohorts
  • At least 2 lesions of measurable disease, unless specified otherwise in the selection criteria
  • Willingness to undergo biopsies
  • Demonstrated adequate organ function within 28 days of Cycle 1 Day 1 (C1D1)
  • Life expectancy >12 weeks as determined by the Investigator
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
  • Participants who have undergone treatment with anti-PD-1, anti-PD-L1, or antiCTLA 4 antibody must have at least 4 weeks from the last dose of antibody and evidence of disease progression per investigator assessment before enrollment
  • Participants who have previously received an immune checkpoint inhibitor prior to enrollment must have any immune related toxicities resolved to ≤Grade 1 or baseline (prior to the checkpoint inhibitor) to be eligible
  • Female and male participants of childbearing potential who are sexually active must agree to use highly effective methods of contraception

Ki nem vehet részt

  • Participants who have been previously treated with a TLR agonist (excluding topical agents for unrelated disease) are not eligible
  • Systemic immunosuppressive treatment with the exception for patients on corticosteroid taper (for example, for chronic obstructive pulmonary disease exacerbation). Participants cannot start dosing on study until steroid dose is at or lower than 10 mg per day prednisone or equivalent
  • Vaccination with live, attenuated vaccines within 4 weeks of enrollment
  • Treatment with any other anti-cancer systemic treatment (approved or investigational) or radiation therapy within 4 weeks of first dosing on study is not allowed
  • Other active malignancies within the last 2 years are excluded
  • Active autoimmune diseases, regardless of need for immunosuppressive treatment at the time of screening, with the exception of patients well controlled on physiologic endocrine replacement
  • Known bleeding disorder that is deemed to place the patient at unacceptable risk for bleeding complications from intratumoral injections or biopsies
  • Known hypersensitivity to any component of TransCon TLR7/8 Agonist or pembrolizumab
  • Any uncontrolled bacterial, fungal, viral, or other infection
  • Significant cardiac disease
  • Positive for HIV or with active hepatitis B or C infection
  • Women who are breastfeeding or have a positive serum pregnancy test during screening or within 72 hours prior to C1D1 are not eligible
  • A marked baseline prolongation of QT/QTc (corrected QT) interval (e.g., repeated demonstration of a QTc interval >480 ms (National Cancer Institute NCI) Common Terminology Criteria for Adverse Events [CTCAE] grade 1) using Fredericia's QT correction formula
  • A history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart failure, clinically significant hypokalemia, family history of Long QT Syndrome)
  • The use of concomitant medications that prolong the QT/QTc interval within 14 days of enrollment
  • Symptomatic central nervous system metastases

Helyszínek itt: Egyesült Államok

Még 5 másik országban, 21 helyszínen

  • Canton, OhioHospital not named in the registry
  • Chicago, IllinoisHospital not named in the registry
  • Cincinnati, OhioHospital not named in the registry
  • Cleveland, OhioHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Duarte, CaliforniaHospital not named in the registry
  • Fairfax, VirginiaHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Iowa City, IowaHospital not named in the registry
  • Knoxville, TennesseeHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Louisville, KentuckyHospital not named in the registry
  • Orange, CaliforniaHospital not named in the registry
  • Pittsburgh, PennsylvaniaHospital not named in the registry
  • San Francisco, CaliforniaHospital not named in the registry
  • Tampa, FloridaHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist every cycle. The primary objectives are to evaluate safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab.

A vizsgálat 3 csoportja

  • Part 1 Monotherapy Dose Escalation and Optimization: TransCon TLR7/8 AgonistA vizsgált kezelés

    TransCon TLR7/8 Agonist in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D.

    Kezelés: TransCon TLR7/8 Agonist

  • Part 2 Combination Dose Escalation and Optimization: TransCon TLR7/8 Agonist with PembrolizumabA vizsgált kezelés

    TransCon TLR7/8 Agonist with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D.

    Kezelés: TransCon TLR7/8 Agonist és Pembrolizumab

  • Part 3 Phase 2 Combination Dose Expansion: TransCon TLR7/8 Agonist with PembrolizumabA vizsgált kezelés

    TransCon TLR7/8 Agonist with Pembrolizumab using RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination in indication-specific dose expansion cohorts.

    Kezelés: TransCon TLR7/8 Agonist és Pembrolizumab

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
A regiszteradat frissítve
2026. április 13.